Trial Profile
Stereoselective pharmacokinetics and CYP2C19-genotyping as outcome predictors of an esomeprazole therapy in patients with GERD -- a pilot study (phase IV-study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Esomeprazole (Primary)
- Indications Reflux oesophagitis
- Focus Pharmacodynamics; Pharmacokinetics
- 30 Jul 2022 Status changed from recruiting to completed.
- 03 May 2012 New trial record